Aspira Pathlab & Diagnostics Ltd.
Snapshot View

56.50 +0.30 ▲0.5%

18 May 2022, 04:01:00 PM
Volume: 452

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.aspiradiagnostics.com
Market Cap 58.16 Cr.
Enterprise Value(EV) 58.71 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 3.35 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 16.88 Trailing Twelve Months Ending 2021-12
Industry PE 42.46 Trailing Twelve Months Ending 2021-12
Book Value / Share 11.01 Trailing Twelve Months Ending 2021-12
Price to Book Value 5.13 Calculated using Price: 56.50
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.03 Cr. 10,293,000 Shares
FaceValue 10
Company Profile
Aspira Pathlab & Diagnostics Limited is a public limited company incorporated and domiciled in India. The company is engaged in the business of running, owning, managing and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.

It has its registered office at Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai, Maharashtra, India.

The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company’s performance, allocate resources based on the analysis of the various performance indicator of the Company as a single unit. 

Business area of the company

The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.53%
1 Week
+3.57%
1 Month
-19.86%
3 Month
-30.38%
6 Month
-38.92%
1 Year
+88.96%
2 Year
+47.52%
5 Year
10 Year
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 3.23 2.55 1.10 0.76 -57.04 -178.61 -187.57 -94.32 22.80
Return on Capital Employed (%) 4.99 3.88 3.95 1.78 -25.35 -38.38 -34.50 -26.30 21.52
Return on Assets (%) 3.22 2.55 1.05 0.54 -25.76 -40.76 -37.93 -29.11 10.58

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 1 1 4 4 6 0 5 4 8 10
Non Curr. Liab. 3 11 5 5 1 2
Curr. Liab. 0 3 6 2 4 5 2 2
Minority Int.
Equity & Liab. 1 1 4 6 15 13 15 14 12 14
Non Curr. Assets 1 11 11 13 11 8 10
Curr. Assets 1 1 4 6 4 2 2 3 4 4
Misc. Exp. not W/O
Total Assets 1 1 4 6 15 13 15 14 12 14

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 1 4 8 8 15 18
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 1 5 8 9 15 18
Total Expenditure 0 0 0 0 -3 -8 -11 -10 -12 -13
PBIDT 0 0 0 0 -2 -4 -3 -2 4 5
Interest 0 0 0 -1 -1 -1 -1 0
Depreciation 0 -1 -1 -2 -1 -1
Taxation 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 -3 -6 -5 -4 1 3
Adjusted EPS 0 0 0 0 -5 -11 -6 -5 1 3

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 -1 -5 -3 -2 6
Cash Fr. Inv. 0 0 0 0 0 -10 -1 -2 0 0
Cash Fr. Finan. 0 3 3 9 7 3 1 -2
Net Change 0 0 3 2 -3 1 -2 0 3
Cash & Cash Eqvt 0 0 3 5 3 0 -2 -2 1

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 40.15 40.15 40.15 40.15 36.25 36.25 36.25 36.25 36.25
Public 59.85 59.85 59.85 59.85 63.75 63.75 63.75 63.75 63.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 14 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company Aspira Pathlab & Diagnostics Ltd
2 CIN NO. L85100MH1973PLC289209
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* FY 2021-2022 FY 2022-2023
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)FY 2020-2021 2021-2022
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-PRIYA PANDEY
Designation :-COMPANY SECRETARY AND COMPLIANCE OFFICER
Name of the Chief Financial Officer :- BALKRISHNA TALAWADEKAR
Designation : -CHIEF FINANCIAL OFFICER

Date: 14/05/2022

Sat, 23 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayAspira Pathlab & Diagnostics Ltd
2CINL85100MH1973PLC289209
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Priya Pandey
Designation: Company Secretary and Compliance Officer
EmailId: priya.pandey@aspiradiagnostics.com
Name of the Chief Financial Officer: Balkrishna Talawadekar
Designation: Chief Financial Officer
EmailId: balkrishna.talawadekar@aspiradiagnostics.com

Date: 23/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Fri, 22 Apr 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Clean EV Technologies Pvt Ltd

Technical Scans View Details

Wed, 18 May 2022
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Decrease 6 Months High Decrease 6 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%